Press Releases

BRISBANE, CA and ST. LOUIS, MO, June 22, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced today the formation of a Scientific Advisory Board (SAB) and appointment of five leading oncology experts.

BRISBANE, CA and ST. LOUIS, MO, April 21, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton to the Company’s Board of Directors.

BRISBANE, CA and ST. LOUIS, MO, August 12, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Drew Dennison to Board of Directors.

BRISBANE, CA and ST. LOUIS, MO, May 22, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Kirk Christoffersen as Chief Business Officer. In this newly-created position, Mr. Christoffersen will lead Arch Oncology’s corporate strategy and other business functions reporting to Julie Cherrington, Ph.D., President and Chief Executive Officer of Arch Oncology.

BRISBANE, CA and ST. LOUIS, MO, March 29, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 therapies for cancer, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, GA.

BRISBANE, CA and ST. LOUIS, MO, March 25, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing. The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.

BRISBANE, CA and ST. LOUIS, MO, February 6, 2019 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of next-generation anti-CD47 antibody therapies for cancer, today announced the initiation of a new Phase 1 clinical trial of AO-176 in select solid tumors with the first patient dosed.